Michael W. Young

Right now, no place in the world is a hotter spot to conduct clinical trials that the Asian-Pacific region (APAC). This popularity of the region is not new. In 2018 China was one of the hottest topics of conversation I heard at the DIA Annual Meeting. Shortly thereafter I wrote an article that featured the insights of three experts on that region. A year later the region was still attracting a lot of excitement when I produced this piece discussing how South Korea was a growing hot spot for… Show more

Right now, no place in the world is a hotter spot to conduct clinical trials that the Asian-Pacific region (APAC). This popularity of the region is not new. In 2018 China was one of the hottest topics of conversation I heard at the DIA Annual Meeting. Shortly thereafter I wrote an article that featured the insights of three experts on that region. A year later the region was still attracting a lot of excitement when I produced this piece discussing how South Korea was a growing hot spot for trials. Today, the entire region remains an area of interest for clinical studies.
The presence of quality CROs is not the only reason to take a close look at APAC. I spoke to industry consultant and Clinical Leader Editorial Board member, Michael W. Young, principal at biomedwoRx: Life Sciences Consulting, for his take on the growing clinical popularity of the region. Show less

Many changes are taking place that are having an impact on the conduct of clinical trials. New tools such as risk-based monitoring (RBM), real-world evidence (RWE), and adaptive trials are helping to fix a process that many believe is fundamentally broken. At the same time, trials are becoming more complex and new guidelines are being placed on sponsors.
What will all of this mean for the conduct of trials in 2020 and beyond?
My work with ScienceMedia recently provided me the opportunity… Show more

Many changes are taking place that are having an impact on the conduct of clinical trials. New tools such as risk-based monitoring (RBM), real-world evidence (RWE), and adaptive trials are helping to fix a process that many believe is fundamentally broken. At the same time, trials are becoming more complex and new guidelines are being placed on sponsors.
What will all of this mean for the conduct of trials in 2020 and beyond?
My work with ScienceMedia recently provided me the opportunity to speak with Michael Brooks, then president of clinical development & commercialization services at Covance. Brooks shared his insights on these topics and several others. Show less

The official publication of LTEN, the national organization for Life Science training and educational professionals, became an excellent forum for discussing the growing complexities of clinical trial development and the real-time needs for education and state-of-the-art trial compliance and execution. Michael W. Young outlines the challenge and pathways to successful trial execution.

Opinion piece on The Evolution from Patient-Centered to Patient-Centric drug development and marketing. What can you do to become truly patient centric? How do you know you’re being respectful and “real world” with patient preferences? Offers four ways to help healthcare marketing professionals attain true patient centricity

PODCAST: The concept of a Fully Integrated Pharmaceutical COmpany (FIPCO) has now become an ecosystem of solid-line and dotted-line collaborating companies, many of which provide processes, data-management, and other services rather than hardgoods / products. Extracting real value and increasing innovation, speed to target, and improved reputation and quality go well beyond the procurement function today. This conversation with Michael explores an expertise he is helping to evolve in the… Show more

PODCAST: The concept of a Fully Integrated Pharmaceutical COmpany (FIPCO) has now become an ecosystem of solid-line and dotted-line collaborating companies, many of which provide processes, data-management, and other services rather than hardgoods / products. Extracting real value and increasing innovation, speed to target, and improved reputation and quality go well beyond the procurement function today. This conversation with Michael explores an expertise he is helping to evolve in the Alliance Management community. Show less

Lead article written for patients and caregivers. This primer provides educational background on the gauntlet which must be run by new drugs being developed for the treatment of Orphan Diseases.

Cross-functional experts from PPD (www.ppdi.com) explore how to optimise trial delivery by effectively integrating central lab capabilities with global clinical development services. (pgs. 28-30)

Association interview about the evolving role of Alliance Managers in maximizing the value of vendor and external partner alliances in delivering services and products. Helps define Development Alliances and Corporate Alliances in the life sciences / drug development arena.

A thorough compilation of Expert advice for patients and families afflicted with this systemic cancer featuring in-depth information about cutaneous lymphoma, treatment options, what it’s like to live with the disease, and how patients can live with the best quality of life possible.

On Screen Speaking Part,: Scientist #1 in an Indie Film & Trailer.
Synopsis: After losing his son, a grieving father stumbles upon a network of people that collect souls preparing them for their journey out of Purgatory. The Father's quest for closure is wonderfully told.in this full-length film which debuted at the La Paloma Theater in Encinitas, CA.
http://www.facebook.com/events/216810655065138/

Fall Newsletter from the Cutaneous Lymphoma Foundation with editorial and Letter from the President.

Article and pictures

Supporting Editor / Author for several sections including Dedication.

A professional industry view toward the corproate, clinical, and commercial value of alliances built wih disease and tumor-focused oncology patient advocacy groups.

These are not the Best of times for the pharmaceutical industry. More regulations, increased federal scrutiny, pricing pressures, and a tarnished public image all cloud the present — and future — of the industry. But along with these challenges come opportunities for meeting professionals — opportunities to not only elevate their status within their companies, but also to help the industry as a whole, said Michael W. Young, senior director, global oncology strategy, Eisai Inc., La Jolla… Show more

These are not the Best of times for the pharmaceutical industry. More regulations, increased federal scrutiny, pricing pressures, and a tarnished public image all cloud the present — and future — of the industry. But along with these challenges come opportunities for meeting professionals — opportunities to not only elevate their status within their companies, but also to help the industry as a whole, said Michael W. Young, senior director, global oncology strategy, Eisai Inc., La Jolla, Calif., the keynote speaker at the Third Annual Pharmaceutical Meeting Planners Forum.
In a forthright, often sober, but ultimately inspiring address, Young, a previous Medical Marketing Association, “Medical Marketer of the Year,” told the nearly 1,000 meeting professionals in the audience at the Pennsylvania Convention Center in Philadelphia that they are “more vital to their organizations than ever before,” serving as logisticians, marketers, strategists, and compliance gatekeepers in today's highly regulated environment. They also play a critical role in improving the beleaguered image of the industry and substantiating the value of pharmaceuticals as a means to save lives and improve the quality of life for patients. Show less